| Dr Sabrina Diane Dinkha, DO | |
|
13750 S Sedona Parkway, Suite 2, Lansing, MI 48906 | |
| (517) 669-9758 | |
| (517) 679-8232 |
| Full Name | Dr Sabrina Diane Dinkha |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 13750 S Sedona Parkway, Lansing, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083877344 | NPI | - | NPPES |
| 1083877344 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 5101017606 (Michigan) | Primary |
| Entity Name | Ascension Michigan-cmg |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851765374 PECOS PAC ID: 7517162761 Enrollment ID: O20160127001523 |
News Archive
The use of invasive procedures for treatment of ischemic heart disease has more than tripled in the past 2 decades and is likely to increase in high-risk patients, according to background information in the article.
Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model.
The U.S. Food and Drug Administration today announced the availability of $2 million in research grants to fund natural history studies in rare diseases. The aim is to collect data on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval. This will be the first time the FDA will provide funding through its Orphan Products Grants to conduct these types of studies for rare diseases.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sabrina Diane Dinkha, DO 804 Service Rd, A201, East Lansing, MI 48824-7015 Ph: (517) 884-2976 | Dr Sabrina Diane Dinkha, DO 13750 S Sedona Parkway, Suite 2, Lansing, MI 48906 Ph: (517) 669-9758 |
News Archive
The use of invasive procedures for treatment of ischemic heart disease has more than tripled in the past 2 decades and is likely to increase in high-risk patients, according to background information in the article.
Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model.
The U.S. Food and Drug Administration today announced the availability of $2 million in research grants to fund natural history studies in rare diseases. The aim is to collect data on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval. This will be the first time the FDA will provide funding through its Orphan Products Grants to conduct these types of studies for rare diseases.
› Verified 6 days ago
Jeanjiko D Cuison, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5135 S Pennsylvania Ave, Lansing, MI 48911 Phone: 517-887-5922 Fax: 517-887-5982 | |
Dr. David Cervi, D.O., PH.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1200 E Michigan Ave Ste 145, Lansing, MI 48912 Phone: 517-364-5440 Fax: 517-364-5409 | |
Ahda Fatehi Mohammad Jbarah, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-997-2000 | |
Harrietta Christodoulos, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1200 E Michigan Ave Ste 145, Lansing, MI 48912 Phone: 517-364-5440 Fax: 517-364-5409 | |
Dr. Renuka Gera, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1200 E Michigan Ave, Ste 145, Lansing, MI 48912 Phone: 517-364-5449 Fax: 517-364-5409 | |
Farrokh Rahnemoon, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 644 Migaldi Ln, Suite 300, Lansing, MI 48917 Phone: 517-627-6024 Fax: 517-627-9339 | |
Dr. Robert Francis Root, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 13750 S Sedona Pkwy Ste 2, Lansing, MI 48906 Phone: 517-353-4000 Fax: 844-722-4112 |